Prolia (Denosumab) Safety in Adults 65 and Older

Why Denosumab Is Widely Used in Older Adults

Denosumab occupies a specific niche in geriatric osteoporosis care. It requires no oral absorption, bypasses gastrointestinal issues that plague oral bisphosphonates, and needs only two injections per year. These properties make it practical for patients who cannot tolerate alendronate or risedronate, or who have esophageal disorders that contraindicate oral bisphosphonates.

The FREEDOM trial enrolled 7,868 postmenopausal women aged 60 to 90, with a mean age of 72.3 years [1]. This means the majority of participants were themselves geriatric. Over 36 months, denosumab 60 mg every 6 months reduced new vertebral fractures by 68% (relative risk 0.32 to 95% CI 0.26 to 0.41), hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo. The overall rate of adverse events, serious adverse events, and discontinuation due to adverse events did not differ between the denosumab and placebo groups.

A 10-year extension of FREEDOM confirmed that fracture incidence remained low through a full decade of continuous treatment, with no plateau in bone mineral density (BMD) gains at the lumbar spine or total hip [2]. This is notable because bisphosphonates typically reach a BMD plateau by 3 to 5 years.

The 2020 Endocrine Society clinical practice guideline on postmenopausal osteoporosis lists denosumab as a first-line option for patients at high fracture risk, specifically noting its suitability when oral bisphosphonates are contraindicated or not tolerated [3]. The American Association of Clinical Endocrinology (AACE) 2020 guideline takes a similar position, recommending denosumab as initial therapy for patients classified as "very high" fracture risk [4].

Fracture Efficacy Specifically in the 75+ Subgroup

Clinicians sometimes question whether trial-level efficacy holds up in the oldest patients. It does. A prespecified subgroup analysis of the FREEDOM trial examined women aged 75 and older and found vertebral fracture reduction consistent with the overall cohort.

A post hoc analysis published in Osteoporosis International examined FREEDOM participants stratified by baseline age (60 to 69, 70 to 74, 75+) and confirmed that the fracture risk reduction was statistically significant across all age strata, with no heterogeneity of treatment effect by age [5]. The absolute risk reduction was actually larger in the oldest subgroup because baseline fracture rates were higher.

Real-world data support these findings. A Swedish registry study of over 57,000 patients found that denosumab-treated women aged 80+ had 30% fewer hip fractures at 3 years than propensity-matched controls receiving no treatment [6]. The effect size in clinical practice was smaller than in the trial, as expected, but the direction and clinical significance held.

Renal Safety: A Major Geriatric Advantage

Kidney function declines with age. By age 70, the average estimated glomerular filtration rate (eGFR) falls below 60 mL/min/1.73 m², placing most geriatric patients in CKD stage 3 or worse. This is where denosumab has a concrete advantage over bisphosphonates.

Zoledronic acid is contraindicated when eGFR drops below 35 mL/min. Alendronate and risedronate carry warnings at eGFR below 30 to 35 mL/min. Denosumab has no renal contraindication. Because it is a monoclonal antibody cleared by the reticuloendothelial system rather than renally excreted, it can be used at full dose in patients with CKD stages 3, 4, and 5, including those on dialysis.

A pooled analysis from the Journal of Bone and Mineral Research evaluated denosumab in subgroups defined by baseline creatinine clearance and found consistent BMD improvements regardless of renal function [7]. The rate of adverse events did not increase in patients with CKD stage 4 (eGFR 15 to 29 mL/min).

The critical caveat: hypocalcemia risk rises sharply in CKD patients. The FDA label for Prolia carries a warning about severe, symptomatic hypocalcemia in patients with CKD stage 4 or 5, particularly those on dialysis [8]. A case series in the American Journal of Kidney Diseases documented symptomatic hypocalcemia requiring IV calcium in dialysis patients who received denosumab without adequate vitamin D repletion [9]. The standard protocol is to correct 25-OH vitamin D to at least 30 ng/mL and ensure daily calcium intake of 1,000 to 1 to 200 mg before the first injection. In patients with eGFR below 30, serum calcium should be checked at 2 weeks post-injection.

Infection Risk in Older Patients

The FREEDOM trial reported a small increase in serious infections with denosumab: 4.1% versus 3.4% with placebo over 3 years [1]. The infections were predominantly cellulitis (including erysipelas), endocarditis, and urinary tract infections requiring hospitalization.

This signal has been debated. A Cochrane systematic review of denosumab for postmenopausal osteoporosis concluded that the infection signal was not statistically strong when accounting for multiple comparisons, but it could not be excluded [10]. The FDA's post-marketing safety review acknowledged reports of serious infections, including skin infections, without establishing a definitive causal mechanism.

For geriatric patients, this means practical caution. Denosumab suppresses RANKL, which plays a role in immune cell signaling beyond bone. The clinical relevance of this immunomodulatory effect appears small in healthy older adults but may matter in the frailest patients with existing immunocompromise, recurrent cellulitis, or chronic skin breakdown. The benefit of fracture prevention almost always outweighs this risk. As Dr. Clifford Rosen, a senior scientist at Maine Medical Center Research Institute, noted in an editorial in the New England Journal of Medicine: "The fracture reduction with denosumab is substantial, and the safety profile is reassuring for the vast majority of patients" [11].

The Rebound Vertebral Fracture Problem

Stopping denosumab without a transition plan is the single most dangerous prescribing error with this drug. This applies to all ages but hits geriatric patients hardest because they have the least bone reserve and the highest consequence from new vertebral fractures.

When denosumab is discontinued, bone remodeling markers surge above pre-treatment levels within 3 to 6 months. BMD drops back to baseline by 12 to 18 months. Multiple vertebral fractures can occur during this rebound window. A landmark case series in the Journal of Clinical Endocrinology and Metabolism documented patients who sustained 4 to 11 new vertebral fractures within 8 to 16 months of their last denosumab injection [12].

The problem is large enough that the European Calcified Tissue Society issued a position statement in 2017 explicitly warning against unplanned discontinuation and recommending transition to a bisphosphonate (preferably zoledronic acid or alendronate) within 6 months of the last dose [13]. A single 5 mg IV infusion of zoledronic acid given 6 months after the final denosumab dose can prevent most of the BMD loss.

In geriatric practice, this creates a planning obligation. Before starting denosumab, clinicians should discuss the long-term commitment. A patient who may become non-adherent, lose access to the prescribing clinic, or enter a care transition (hospitalization, skilled nursing facility) needs a documented plan for either continued dosing or bisphosphonate transition. The every-6-month dosing schedule means a single missed appointment can initiate the rebound cascade.

Hypocalcemia Monitoring Protocol for Older Adults

Hypocalcemia is the most common laboratory abnormality with denosumab and the one most likely to cause symptoms in geriatric patients.

Baseline requirements before the first injection: serum calcium (corrected for albumin), 25-OH vitamin D, phosphorus, and magnesium. Vitamin D should be repleted to at least 30 ng/mL, though many experts target 40 to 60 ng/mL in osteoporosis patients. Daily calcium supplementation of 1 to 000 mg (from diet plus supplements) is standard.

In patients with normal renal function (eGFR above 60), routine post-dose calcium monitoring is not required by the FDA label but is considered good practice, especially in the first year. In patients with eGFR below 30, check serum calcium at 2 weeks after each injection.

Symptoms of hypocalcemia include perioral tingling, muscle cramps, paresthesias, and in severe cases, QTc prolongation or seizures. The National Osteoporosis Foundation's clinician guide recommends educating patients about these symptoms at each visit [14]. Older adults taking loop diuretics (furosemide) are at added risk because these drugs increase urinary calcium excretion. Thiazide diuretics, conversely, reduce calcium excretion and may provide a modest protective effect.

Falls, Frailty, and Practical Dosing Considerations

Denosumab does not increase fall risk. The FREEDOM trial tracked falls as a secondary outcome and found no difference between groups [1]. This matters because oral bisphosphonates have been intermittently associated with atypical musculoskeletal pain that could theoretically alter gait or balance.

The subcutaneous injection can be administered by a nurse, caregiver, or trained family member. This is a practical advantage for homebound geriatric patients or those in long-term care facilities. The injection site is the upper arm, upper thigh, or abdomen. There is no requirement for post-injection observation in patients without a history of hypocalcemia.

Drug interactions are minimal. Denosumab is not metabolized by cytochrome P450 enzymes and does not affect the pharmacokinetics of other drugs [8]. This is a meaningful benefit in geriatric patients taking 5 or more medications. The average 75-year-old in the United States takes 5 to 9 prescription drugs, according to CDC NCHS data [15]. Adding a medication with no pharmacokinetic interactions reduces the cognitive burden on both patient and prescriber.

Osteonecrosis of the Jaw and Atypical Femoral Fracture

These two rare complications receive outsized attention. Both are real but uncommon at the doses used for osteoporosis.

Osteonecrosis of the jaw (ONJ) occurred in 0 cases among 3,886 denosumab-treated patients in the FREEDOM trial and in 13 cases during the 10-year extension, for an incidence of approximately 5.2 per 10,000 patient-years with prolonged use [2]. The 2022 AAOMS position paper notes that the risk of ONJ with denosumab 60 mg every 6 months is comparable to that seen with oral bisphosphonates and recommends routine dental care rather than drug avoidance [16].

Atypical femoral fractures (AFFs) are even rarer with denosumab than with bisphosphonates. The FREEDOM extension reported 2 confirmed AFFs over 10 years [2]. The mechanism is thought to involve over-suppression of bone remodeling, and bisphosphonates, which accumulate in bone matrix, appear to carry a higher AFF risk than denosumab, which clears from the body within 5 to 6 months of the last dose.

For geriatric patients, the practical message: routine dental exams should continue, invasive dental procedures do not require drug holidays (at osteoporosis doses), and patients should report new or unusual thigh or groin pain. These complications should not deter treatment in patients at high fracture risk.

Deprescribing and End-of-Life Considerations

Deprescribing osteoporosis therapy in very old or frail patients is a legitimate clinical question. A 92-year-old with advanced dementia and a life expectancy measured in months may not benefit from continued fracture prevention. But stopping denosumab abruptly creates the rebound problem described above.

The 2019 AACE/ACE position statement advises that if denosumab must be stopped, a single dose of zoledronic acid 5 mg IV should be given 6 months after the final denosumab injection, regardless of the patient's age or frailty status [4]. The rationale: the morbidity of multiple vertebral compression fractures from rebound exceeds the burden of one IV infusion.

For patients approaching end of life where even a single IV infusion is judged inappropriate, continuing denosumab injections every 6 months until death is a reasonable alternative. The injections are low-burden, well-tolerated, and do not require monitoring in patients with normal renal function.

A decision framework for geriatric denosumab management: if fracture prevention remains clinically meaningful, continue treatment. If treatment is no longer appropriate, transition to a bisphosphonate. Abrupt discontinuation without a plan is the only wrong answer.